[go: up one dir, main page]

BR0308360A - Composição termossensìvel sob forma liquida, organogel obtido a partir da composição, utilização de uma composição e processo de preparação de uma composição - Google Patents

Composição termossensìvel sob forma liquida, organogel obtido a partir da composição, utilização de uma composição e processo de preparação de uma composição

Info

Publication number
BR0308360A
BR0308360A BR0308360-8A BR0308360A BR0308360A BR 0308360 A BR0308360 A BR 0308360A BR 0308360 A BR0308360 A BR 0308360A BR 0308360 A BR0308360 A BR 0308360A
Authority
BR
Brazil
Prior art keywords
composition
organogel
heat
liquid form
sensitive
Prior art date
Application number
BR0308360-8A
Other languages
English (en)
Other versions
BRPI0308360B8 (pt
BR0308360B1 (pt
Inventor
Jean-Christophe Leroux
Ane-Claude Couffin-Hoarau
Original Assignee
Ethypharm Sa
Univ Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0203059A external-priority patent/FR2837099B1/fr
Application filed by Ethypharm Sa, Univ Montreal filed Critical Ethypharm Sa
Publication of BR0308360A publication Critical patent/BR0308360A/pt
Publication of BR0308360B1 publication Critical patent/BR0308360B1/pt
Publication of BRPI0308360B8 publication Critical patent/BRPI0308360B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO TERMOSSENSìVEL SOB FORMA LìQUIDA, ORGANOGEL OBTIDO A PARTIR DA COMPOSIçãO, UTILIZAçãO DE UMA COMPOSIçãO E PROCESSO DE PREPARAçãO DE UMA COMPOSIçãO". A presente invenção trata de uma composição termossensível sob forma líquida contendo um líquido orgânico hidrofóbico, uma substância organogelificante cujas moléculas têm a capacidade de se ligar entre si por ligações de baixa energia, e uma substância bioativa, que passa para a forma de organogel quando ela entra em contato com um líquido fisiológico, durante sua administração a um corpo animal, em particular o homem.
BRPI0308360A 2002-03-12 2003-03-12 composição termossensível sob forma liquida compreendendo substância organogelificante, utilização de uma composição e processo de preparação de uma composição BRPI0308360B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0203059A FR2837099B1 (fr) 2002-03-12 2002-03-12 Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives
US40572002P 2002-08-26 2002-08-26
PCT/FR2003/000797 WO2003075885A1 (fr) 2002-03-12 2003-03-12 Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives

Publications (3)

Publication Number Publication Date
BR0308360A true BR0308360A (pt) 2005-01-25
BR0308360B1 BR0308360B1 (pt) 2017-11-14
BRPI0308360B8 BRPI0308360B8 (pt) 2021-05-25

Family

ID=27806677

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308360A BRPI0308360B8 (pt) 2002-03-12 2003-03-12 composição termossensível sob forma liquida compreendendo substância organogelificante, utilização de uma composição e processo de preparação de uma composição

Country Status (12)

Country Link
US (1) US7691408B2 (pt)
EP (1) EP1485066B1 (pt)
JP (1) JP2005528352A (pt)
CN (1) CN100584314C (pt)
AU (1) AU2003227827B2 (pt)
BR (1) BRPI0308360B8 (pt)
CA (1) CA2478825C (pt)
IL (1) IL164031A (pt)
MX (1) MXPA04008906A (pt)
NO (1) NO339426B1 (pt)
NZ (1) NZ535270A (pt)
WO (1) WO2003075885A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691408B2 (en) 2002-03-12 2010-04-06 Ethypharm Composition having gelling properties for the prolonged delivery of bioactive substances
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
GB2438544A (en) * 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ATE553659T1 (de) * 2006-07-24 2012-05-15 Unilever Nv Ausgangsstoff für ein getränk
JP2010531807A (ja) 2007-05-25 2010-09-30 トルマー セラピューティクス， インコーポレイテッド リスペリドン化合物の徐放送達製剤
FR2926996B1 (fr) * 2008-01-31 2013-06-21 Ethypharm Sa Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
ES2524580T3 (es) 2010-09-03 2014-12-10 Santen Sas Una emulsión de tipo agua en aceite para tratar una enfermedad de los ojos
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
SI2425814T1 (sl) * 2010-09-03 2013-10-30 Novagali Pharma S.A. Emulzija vrste voda-v-olju za zdravljenje bolezni očesa
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
JP6992057B2 (ja) 2016-06-10 2022-01-13 クラリティ コスメティックス インコーポレイテッド 非面皰形成性の毛髪および頭皮ケア製剤ならびにその使用方法
CN108479649A (zh) * 2018-05-10 2018-09-04 哈尔滨工业大学 一种有机凝胶的制备方法与应用
US20240415765A1 (en) * 2021-12-24 2024-12-19 Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. Continuous delivery preparation capable of being stably released and preparation method therefor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932624A (en) 1974-06-17 1976-01-13 Morton-Norwich Products, Inc. Method for prolonging the inhibitory effect of saralasin on angiotensin II
US3969087A (en) 1974-08-07 1976-07-13 Ajinomoto Co., Ltd. Gels of nonpolar liquids with N-acyl amino acids and derivatives thereof as gelling agents
JPS5119139A (ja) * 1974-08-07 1976-02-16 Ajinomoto Kk Gerujokeshoryososeibutsu
US5575815A (en) 1988-08-24 1996-11-19 Endoluminal Therapeutics, Inc. Local polymeric gel therapy
SI9300468A (en) 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
EP0725620B1 (en) * 1993-10-18 2001-03-14 The Procter & Gamble Company Non-sweating lipsticks
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US20010007673A1 (en) 1999-11-12 2001-07-12 Merrill Seymour Goldenberg Sustained-release delayed gels
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6306383B1 (en) 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
FR2794998B1 (fr) * 1999-06-21 2001-07-27 Oreal Organogels et leurs utilisations notamment cosmetiques
FR2795360B1 (fr) 1999-06-24 2001-12-14 Technologique De Prec Mecaniqu Procede de fabrication d'articles de conditionnement et machine de fabrication correspondante
US7691408B2 (en) 2002-03-12 2010-04-06 Ethypharm Composition having gelling properties for the prolonged delivery of bioactive substances

Also Published As

Publication number Publication date
IL164031A (en) 2010-11-30
CN100584314C (zh) 2010-01-27
NO339426B1 (no) 2016-12-12
EP1485066B1 (fr) 2016-09-21
CA2478825C (fr) 2012-01-24
MXPA04008906A (es) 2005-09-08
HK1071704A1 (zh) 2005-07-29
AU2003227827A1 (en) 2003-09-22
NZ535270A (en) 2006-11-30
CN1649567A (zh) 2005-08-03
JP2005528352A (ja) 2005-09-22
US20060121115A1 (en) 2006-06-08
AU2003227827B2 (en) 2008-09-25
BRPI0308360B8 (pt) 2021-05-25
NO20044310L (no) 2004-10-12
CA2478825A1 (fr) 2003-09-18
BR0308360B1 (pt) 2017-11-14
US7691408B2 (en) 2010-04-06
WO2003075885A1 (fr) 2003-09-18
EP1485066A1 (fr) 2004-12-15

Similar Documents

Publication Publication Date Title
BR0308360A (pt) Composição termossensìvel sob forma liquida, organogel obtido a partir da composição, utilização de uma composição e processo de preparação de uma composição
ES2066896T3 (es) Forma oral de farmaco de lipidos.
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
BR0209777A (pt) Formulações lìquidas estáveis
BRPI0614087B8 (pt) seringa de uso único com sistema de redução de impulso
BRPI0909352A2 (pt) dispositivo terapêutico e que pode ser colocado em contato com um paciente para terapeuticamento resfriar o paciente, sistema para regularizar terapeuticamente a temperatura do corpo de um paciente, método terapêutico para regularizar a temperatura do corpo de um paciente método para terapeuticamente resfriar a temperatura do corpo de um paciente, invólucro, e, envoltório.
DE602004023605D1 (de) Verbesserter einwegapplikator für topische zusammensetzung
BRPI0507026A (pt) proteìnas de fusão de albumina
BR0205484A (pt) Sistema condutor de lìquido ou vapor, com uma zona de junção de uma composição de camadas múltiplas coextrudada
BRPI0415872A (pt) ácidos nucleìcos ligando especificamente à grelina bioativa
ATE463266T1 (de) Vaskuläre biologisch abbaubare vorrichtung enthaltend einen ph-puffer
BRPI0519241A2 (pt) agonistas, composiÇÕes, mÉtodos e usos de glp-1
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
BR0014404A (pt) Artigo absorvente com um dispositivo central de ascensão
BR0311897A (pt) Sistema de liberação osmótica com mecanismo de potência de impulso de ordem zero inicial compreendendo um agente osmótico disperso no veìculo fluido
BRPI0509659A8 (pt) Processo para a preparação de uma composição de polímero de dispersão aquosa
BR0304937B1 (pt) composição de antiespumante de silicone encapsulado e processo para a produção de uma composição de antiespumante de silicone encapsulado.
AR043783A1 (es) Difenilazetidinona con propiedades fisiologicas, medicamentos que comprenden este compuesto y su uso
BRPI0500311A (pt) processo de preparação de uma composição de tratamento cosmético das matérias queratìnicas, composição de tratamento cosmético das matérias queratìnicas, processos de tratamento cosmético das matérias queratìnicas, dispositivo de condicionamento de uma composição cosmética e uso de uma composição
MA29481B1 (fr) Derives d'azolopyridine-2-one en tant qu'inhibiteurs de lipase et de phospholipase
BRPI0418005B8 (pt) composição farmacêutica de dinflunina, utilização de uma composição, e, processo de preparação de uma composição
WO2008070853A3 (en) Apparatus for altering the body temperature of a patient and administering decompression to the patient's torso
AR025391A1 (es) Procedimiento para aplicar a chorro un preparado en fase liquida que contenga un principio activo sobre un sustrato plano
BR0318575A (pt) método para preparar dispositivos médicos para eluição de fármacos e dispositivo obtido deles
ATE333239T1 (de) Medizinischer spatel

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2105 DE 10/05/2011.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2662 DE 11-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.